<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00505323</url>
  </required_header>
  <id_info>
    <org_study_id>2007-A00100-53</org_study_id>
    <secondary_id>PHRC N 2007 DURIF</secondary_id>
    <nct_id>NCT00505323</nct_id>
  </id_info>
  <brief_title>Motor and Premotor Cortex Stimulation for Treatment of Secondary Focal Dystonia With Striato Palliadal Lesion : Evaluation of Safety and Effectiveness</brief_title>
  <acronym>CORDYS</acronym>
  <official_title>Motor and Premotor Cortex Stimulation for Treatment of Secondary Focal Dystonia With Striato Pallidal Lesion : Evaluation of Safety and Effectiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Dystonia is a neurological movement disorder in which sustained muscle contractions cause&#xD;
      twisting and repetitive movements or abnormal postures. This disease is very heterogeneous&#xD;
      and can have many causes. Current treatments (drugs, pallidal stimulation) improve primary&#xD;
      generalized dystonias; however they are ineffective for focal dystonias following brain&#xD;
      damage.&#xD;
&#xD;
      Cortex stimulation is a present and effective technique used in the treatment of chronic pain&#xD;
      and could represent an interesting strategy to treat focal dystonias. This is the aim of the&#xD;
      present study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot study included 6 centres (Clermont-Ferrand, Bordeaux, Paris, Créteil, Lyon and&#xD;
      Grenoble)&#xD;
&#xD;
      Study progress :&#xD;
&#xD;
        -  3 months to 1 month before chirurgical intervention : selection of patient that could be&#xD;
           included in the protocol.&#xD;
&#xD;
        -  15 days to 8 days before chirurgical intervention : inclusion visit.&#xD;
&#xD;
        -  Operating phase : under anaesthesia, implantation of the neurostimulator and its&#xD;
           components, and adjustment of stimulation parameters.&#xD;
&#xD;
        -  1 month after chirurgical intervention : checking that all is fine (detection of&#xD;
           undesirable events)&#xD;
&#xD;
        -  2 months to 5 months after chirurgical intervention: randomization (double blind): the&#xD;
           stimulator is put on position On or OFF&#xD;
&#xD;
        -  5 months after chirurgical intervention : Stimulators of all patients are stopped for&#xD;
           one month whatever the group they belong.&#xD;
&#xD;
        -  6 months to 9 months after chirurgical intervention: Stimulatiors are put on position On&#xD;
           or OFF (cross over with the first period).&#xD;
&#xD;
        -  9 months to 13 months after chirurgical intervention: Stimulators of all patients are&#xD;
           started for four months whatever the group they belong.&#xD;
&#xD;
        -  13 months after chirurgical intervention : study end&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of dystonia by using the validated &quot;Burke Fahn and Marsden (1985)&quot; dystonia rating scale</measure>
    <time_frame>before the chirurgical intervention and 2, 5, 6, 9 and 13 months after</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of spasticity (Ashworth), of akinesy (Tapping score), of pain (EVA test), of quality of life (SF 36 scale) and of undesirable events.</measure>
    <time_frame>before the chirurgical intervention and 2, 5, 6, 9 and 13 months after</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Focal Dystonia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of neurostimulators and their auxiliary components</intervention_name>
    <description>Implantation neurostimulators and their auxiliary components :&#xD;
Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age : &gt;18 years and &lt; 65 years&#xD;
&#xD;
          -  Evolution time of dystonia &gt; 1 year&#xD;
&#xD;
          -  Clinical stability of dystonia = 1 year&#xD;
&#xD;
          -  Secondary dystonia due to a focal lesion (vascular or anoxic) of central grey nuclei&#xD;
&#xD;
          -  Inefficiency of others treatments (anticholinergic, benzodiazepine, neuroleptique,&#xD;
             botulinum toxin, etc.)&#xD;
&#xD;
          -  Stability of treatment &gt;3 months&#xD;
&#xD;
          -  Agreement of patients&#xD;
&#xD;
          -  Affiliation to social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant heart vascular disease; significant respiratory, metabolic, renal or&#xD;
             hepatic diseases&#xD;
&#xD;
          -  Significant clinical and biological anomalies&#xD;
&#xD;
          -  Disease or treatment in favour in bleeding&#xD;
&#xD;
          -  Sever cognitive disorders&#xD;
&#xD;
          -  Psychiatric evolutionary pathology&#xD;
&#xD;
          -  Counter-indication during inclusion examination&#xD;
&#xD;
          -  Chirurgical counter-indication&#xD;
&#xD;
          -  Pregnant women ou women who nurse&#xD;
&#xD;
          -  Person who participate to an other study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck DURIF, Pr</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2007</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cortex stimulation</keyword>
  <keyword>Focal secondary Dystonia</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Quality of life improvement</keyword>
  <keyword>Focal dystonias secondary to central grey nuclei lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

